Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James H Maccabe

Showing results (61-70 of 137) with videos related to

Pageof 14
Sort By:
Psychopharmacology|October 30, 2017
Antipsychotic polypharmacy prescribing and risk of hospital readmissionGiouliana Kadra, Robert Stewart, Hitesh Shetty, et al.
The British Journal of Psychiatry : the Journal of Mental Science|November 29, 2014
Prevalence of serum N-methyl-D-aspartate receptor autoantibodies in refractory psychosisKatherine Beck, John Lally, Sukhwinder S Shergill, et al.
The British Journal of Psychiatry : the Journal of Mental Science|January 20, 2022
Clozapine-induced myocarditis: electronic health register analysis of incidence, timing, clinical markers and diagnostic accuracyAviv Segev, Ehtesham Iqbal, Theresa A McDonagh, et al.
The American Journal of Psychiatry|July 29, 2017
Mortality and Self-Harm in Association With Clozapine in Treatment-Resistant SchizophreniaTheresa Wimberley, James H MacCabe, Thomas M Laursen, et al.
The British Journal of Psychiatry : the Journal of Mental Science|January 20, 2022
Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysisDan Siskind, Stacy Orr, Surabhi Sinha, et al.
Schizophrenia Research|September 9, 2017
Sodium valproate and clozapine induced neutropenia: A case control study using register dataSteffi Malik, John Lally, Olesya Ajnakina, et al.
Therapeutic Advances in Psychopharmacology|October 22, 2021
Outcomes in treatment-resistant schizophrenia: symptoms, function and clozapine plasma concentrationsAmir Krivoy, Eromona Whiskey, Henrietta Webb-Wilson, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|February 13, 2022
COVID-related hospitalization, intensive care treatment, and all-cause mortality in patients with psychosis and treated with clozapineRisha Govind, Daniela Fonseca de Freitas, Megan Pritchard, et al.
Journal of Psychopharmacology (Oxford, England)|June 22, 2012
Granulocyte colony stimulating factor (G-CSF) can allow treatment with clozapine in a patient with severe benign ethnic neutropaenia (BEN): a case reportBenjamin W J Spencer, Hugh R J Williams, Siobhan H Gee, et al.
Journal of Psychopharmacology (Oxford, England)|January 9, 2019
Risk of readmission in patients with schizophrenia and schizoaffective disorder newly prescribed clozapineJad Kesserwani, Giouliana Kadra, Johnny Downs, et al.
Pageof 14

Showing results (61-70 of 137) with videos related to

Sort By:
Pageof 14
Psychopharmacology|October 30, 2017
Antipsychotic polypharmacy prescribing and risk of hospital readmissionGiouliana Kadra, Robert Stewart, Hitesh Shetty, et al.
The British Journal of Psychiatry : the Journal of Mental Science|November 29, 2014
Prevalence of serum N-methyl-D-aspartate receptor autoantibodies in refractory psychosisKatherine Beck, John Lally, Sukhwinder S Shergill, et al.
The British Journal of Psychiatry : the Journal of Mental Science|January 20, 2022
Clozapine-induced myocarditis: electronic health register analysis of incidence, timing, clinical markers and diagnostic accuracyAviv Segev, Ehtesham Iqbal, Theresa A McDonagh, et al.
The American Journal of Psychiatry|July 29, 2017
Mortality and Self-Harm in Association With Clozapine in Treatment-Resistant SchizophreniaTheresa Wimberley, James H MacCabe, Thomas M Laursen, et al.
The British Journal of Psychiatry : the Journal of Mental Science|January 20, 2022
Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysisDan Siskind, Stacy Orr, Surabhi Sinha, et al.
Schizophrenia Research|September 9, 2017
Sodium valproate and clozapine induced neutropenia: A case control study using register dataSteffi Malik, John Lally, Olesya Ajnakina, et al.
Therapeutic Advances in Psychopharmacology|October 22, 2021
Outcomes in treatment-resistant schizophrenia: symptoms, function and clozapine plasma concentrationsAmir Krivoy, Eromona Whiskey, Henrietta Webb-Wilson, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|February 13, 2022
COVID-related hospitalization, intensive care treatment, and all-cause mortality in patients with psychosis and treated with clozapineRisha Govind, Daniela Fonseca de Freitas, Megan Pritchard, et al.
Journal of Psychopharmacology (Oxford, England)|June 22, 2012
Granulocyte colony stimulating factor (G-CSF) can allow treatment with clozapine in a patient with severe benign ethnic neutropaenia (BEN): a case reportBenjamin W J Spencer, Hugh R J Williams, Siobhan H Gee, et al.
Journal of Psychopharmacology (Oxford, England)|January 9, 2019
Risk of readmission in patients with schizophrenia and schizoaffective disorder newly prescribed clozapineJad Kesserwani, Giouliana Kadra, Johnny Downs, et al.
Pageof 14